Welldoc Appoints Michael Acker as Chief Growth Officer

Digital health veteran brings more than 20 years of experience scaling population health and healthcare technology businesses to accelerate Welldoc's commercial expansion

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc^®, a leader in AI-powered health technology for complex conditions, today announced the appointment of Michael Acker as Chief Growth Officer. He will lead Welldoc's commercial strategy and partnerships, working with health plans, life sciences, and health systems to scale programs for people with complex health needs.

“Michael has spent his career building and scaling healthcare businesses, and he brings a rare combination of deep industry experience and a sharp understanding of the technology landscape,” said Kevin McRaith, President and CEO of Welldoc. “As we enter our next phase of growth, he's the right leader to shape our commercial strategy and expand our reach with health plans, health systems, and life sciences companies.”

Most recently, Acker served as Executive Vice President and General Manager of Sharecare's Population Health business, where he led growth across a broad portfolio of digital and population health solutions for large employers, health plans, and government agencies. He worked with healthcare organizations to turn emerging technologies and evidence-based interventions into scalable programs with proven impact. Earlier in his career, he was instrumental in developing and commercializing the Blue Zones Project, a population health model deployed in communities across the United States.

“As AI reshapes care, healthcare organizations want a partner whose results they can measure,” said Acker. “Welldoc has spent years building that evidence, with 11 FDA 510(k) clearances, 69 patents, and more than 100 clinical publications. It's the foundation for helping industry leaders build on the programs they already have and bring the next generation of AI-powered care to people navigating chronic conditions.”

About Welldoc

Welldoc^® is an AI-powered health technology company integrating personalized, real-time and actionable insights into the daily lives of individuals living with complex conditions, enabling improved health and outcomes. Welldoc’s comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc has recently expanded their capabilities beyond cardiometabolic health to other complex areas, including brain health, oncology and immunology. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs.

Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform and holds a portfolio of 69 patents for its AI and technology. With over 100 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc has been showcased in prestigious conferences and publications, including South by Southwest, the Wall Street Journal and the Economist. The company has been recognized extensively, including Time’s Top Health Tech Companies for the past two years, the “Best Overall Digital Health Company” by MedTech Breakthrough for the past four years, and the 2025 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group. For more information, visit www.welldoc.com.